A study on Sabinsa’s Boswellia cream for treatment of psoriasis, Clinical Evaluation of AKBBA in the management of psoriasis, was published in Clinical Dermatology 2014; 2 (1): 17-24. U.S. clinical trials, intended to have AKBBA eventually approved as a drug by FDA for psoriasis, will begin in the near future. This will be a significant step for a nutraceutical company in USA.
The cream of Boswellia serrata Roxb extract standardized for 5% of 95% 3-O-Acetyl-11-Keto Beta Boswellic Acid (AKBBA) was studied in an open-label, multi-centered phase III clinical trial, evaluating 200 psoriatic patients with application of AKBBA cream three times daily for a period of 12 weeks. The researchers observed significant changes in LTB4 (p<0.001) & TNF alpha (p<0.01) values from the baseline along with significant changes (p<0.05) in VEGF & PGE2. Reduction in ‘modified’ PASI score from the baseline visit was in consensus with the global evaluations by physician and patients.
The evidence shows superior anti-inflammatory responses rates, demonstrating that this non-toxic treatment is beneficial for those suffering from this condition.
Although far from the scope of a dietary supplement, the exploratory process that has gone into such a traditional ingredient showcases Sabinsa’s passion for applying modern day technology to traditional botanicals to help create natural solutions for health.
“Our understanding of this ingredient, originating from one of the earliest compounds released by Sabinsa, called Boswellin®, is growing, and we want the world to know the positive research and the impact it has on human health,” said Sabinsa founder Dr. Muhammed Majeed. “Such indications prevalent in Ayurvedic texts are now being proven by modern research, in terms of correctly standardizing, isolating the unique compound(s) and ultimately formulating safe and effective products.”
The cream product is sold and marketed as a drug in India. Sabinsa holds several patents for this and other uses of Boswellia.
The study can be accessed here: bit.ly/AKBBA